

Continuing Education/Continuing Medical Education (CE/CME)

**An introduction to TIL (Tumor-infiltrating lymphocyte) therapy in Metastatic Melanoma**

WHEN: October 30, 2025 — 5:00 PM

**Presentation purpose:**

* Tumor Infiltrating Lymphocyte (TIL) Therapy is a new approach in the treatment of metastatic melanoma and this science may lead to the treatment of other cancers in the future.

**ANCC objectives:**

1 Explain how melanoma played a part in developing this treatment

2 Explain the process of Tumor Infiltrating Lymphocyte (TIL) therapy

3 Discuss the management and care of TIL patients

4 Explore the potential of TIL therapy in other diseases

**Target audience:**

This activity is designed for the interdisciplinary audience including the following:

Specialties: Oncology, Surgery

**Accreditation**

In support of improving patient care, Ascension is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Credit designation:**



This activity was planned by and for the healthcare team, and learners will receive 1.50 IPCE credit(s) for learning and change.





This activity is awarded 1.50 ANCC contact hour(s). (based on 60 minutes per contact hour)











**Faculty/Course Director/Planners:**

Ascension has selected all faculty participating in this activity. It is the policy of Ascension that all CE/CME planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

**Conflict of Interest:**

In accordance with the ACCME Standards for Commercial Support, it is the policy of Ascension to ensure balance, independence, objectivity and scientific rigor in all CE/CME activities.

Full disclosure of conflicts and conflict resolution will be made in writing via handout materials or syllabus.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Tari Hopper, BSN | Activity Coordinator | Nothing to disclose - 07/17/2025 |
| Jatandra Birney, PharmD, BCOP | Faculty | Nothing to disclose - 08/05/2025 |

**Commercial Support:**

No commercial interest was received for this CE/CME activity.